JP2017501202A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501202A5
JP2017501202A5 JP2016544410A JP2016544410A JP2017501202A5 JP 2017501202 A5 JP2017501202 A5 JP 2017501202A5 JP 2016544410 A JP2016544410 A JP 2016544410A JP 2016544410 A JP2016544410 A JP 2016544410A JP 2017501202 A5 JP2017501202 A5 JP 2017501202A5
Authority
JP
Japan
Prior art keywords
nicotinamide
pyridin
cyano
fluoro
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016544410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501202A (ja
JP6475252B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/010006 external-priority patent/WO2015103453A1/en
Publication of JP2017501202A publication Critical patent/JP2017501202A/ja
Publication of JP2017501202A5 publication Critical patent/JP2017501202A5/ja
Application granted granted Critical
Publication of JP6475252B2 publication Critical patent/JP6475252B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016544410A 2014-01-03 2015-01-02 ヘテロアリール置換のニコチンアミド化合物 Expired - Fee Related JP6475252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461923403P 2014-01-03 2014-01-03
US61/923,403 2014-01-03
PCT/US2015/010006 WO2015103453A1 (en) 2014-01-03 2015-01-02 Heteroaryl substituted nicotinamide compounds

Publications (3)

Publication Number Publication Date
JP2017501202A JP2017501202A (ja) 2017-01-12
JP2017501202A5 true JP2017501202A5 (2) 2018-12-13
JP6475252B2 JP6475252B2 (ja) 2019-02-27

Family

ID=52355270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544410A Expired - Fee Related JP6475252B2 (ja) 2014-01-03 2015-01-02 ヘテロアリール置換のニコチンアミド化合物

Country Status (21)

Country Link
US (1) US9169252B2 (2)
EP (1) EP3089973B1 (2)
JP (1) JP6475252B2 (2)
KR (1) KR20160101191A (2)
CN (1) CN106061967B (2)
AR (1) AR098991A1 (2)
AU (1) AU2015204045A1 (2)
CA (1) CA2935329A1 (2)
CL (1) CL2016001706A1 (2)
EA (1) EA201691343A1 (2)
ES (1) ES2804707T3 (2)
IL (1) IL246474A0 (2)
MA (1) MA39162A1 (2)
MX (1) MX2016008723A (2)
PE (1) PE20161292A1 (2)
PH (1) PH12016501164A1 (2)
SG (1) SG11201605340QA (2)
TN (1) TN2016000271A1 (2)
TW (1) TW201609693A (2)
UY (1) UY35935A (2)
WO (1) WO2015103453A1 (2)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150079963A (ko) 2012-11-08 2015-07-08 브리스톨-마이어스 스큅 컴퍼니 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물
CN104781251B (zh) 2012-11-08 2016-12-14 百时美施贵宝公司 可作为激酶调节剂的经双环杂环取代的吡啶基化合物
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
HRP20201384T1 (hr) * 2014-01-01 2020-11-27 Medivation Technologies Llc Spojevi i postupci njihove upotrebe
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
TW201718571A (zh) 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
ES2822956T3 (es) * 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo
WO2016210036A1 (en) 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
GB201518456D0 (en) * 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
KR102688509B1 (ko) * 2017-08-04 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
CA3075892C (en) 2017-09-14 2024-01-23 Daiichi Sankyo Company, Limited Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TW201927769A (zh) * 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ii
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2019160915A1 (en) 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
TWI842978B (zh) * 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス, インコーポレイテッド Irak分解剤およびそれらの使用
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021026181A1 (en) * 2019-08-06 2021-02-11 Bristol-Myers Squibb Company Bicyclic heterocyclic compounds useful as irak4 inhibitors
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4100408B1 (en) 2020-02-03 2024-02-28 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
EP4107158A1 (en) 2020-02-19 2022-12-28 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
PH12023500015A1 (en) 2020-12-30 2024-03-11 Kymera Therapeutics Inc Irak degraders and uses thereof
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
KR20230019396A (ko) * 2021-07-29 2023-02-08 프라비바이오 주식회사 신규 벤젠 유도체 및 이의 면역억제 관련 용도
FI4367118T3 (fi) 2021-08-18 2025-04-09 Nurix Therapeutics Inc Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
WO2025151602A1 (en) * 2024-01-11 2025-07-17 Bristol-Myers Squibb Company Heteroaryl compounds as ligand directed degraders of irak4
WO2025151728A1 (en) * 2024-01-12 2025-07-17 Bristol-Myers Squibb Company Ligand directed degrader of irak4
CN118388401B (zh) * 2024-06-28 2024-08-20 成都凯斯坦生物医药有限公司 一种4-氨基-2-氯烟醛的制备方法
CN118641677B (zh) * 2024-08-16 2024-11-05 北京京丰制药集团有限公司 尼可刹米原料中杂质的检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
US6825190B2 (en) 2001-06-15 2004-11-30 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
CA2531401A1 (en) 2003-07-10 2005-01-27 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
KR20100020454A (ko) 2007-06-08 2010-02-22 바이엘 크롭사이언스 소시에떼아노님 살진균제 헤테로사이클릴-피리미디닐-아미노 유도체
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
WO2010061971A1 (ja) * 2008-11-28 2010-06-03 興和株式会社 ピリジン-3-カルボキシアミド誘導体
EP2440204B1 (en) * 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
EP2493863B1 (en) 2009-10-30 2015-02-25 Janssen Pharmaceutica NV Phenoxy-substituted pyrimidines as opioid receptor modulators
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Gpr119 작동약
CN103619854A (zh) 2011-04-29 2014-03-05 西奈山伊坎医学院 激酶抑制剂
US9074384B2 (en) * 2011-07-27 2015-07-07 Intex Recreation Corp. Combined swimming pool ladder structure
EP2802576B1 (en) 2012-01-13 2018-06-27 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
CN104254533B (zh) 2012-01-13 2017-09-08 百时美施贵宝公司 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
CN104781251B (zh) * 2012-11-08 2016-12-14 百时美施贵宝公司 可作为激酶调节剂的经双环杂环取代的吡啶基化合物
US9315494B2 (en) 2012-11-08 2016-04-19 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
KR20150079963A (ko) * 2012-11-08 2015-07-08 브리스톨-마이어스 스큅 컴퍼니 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물

Similar Documents

Publication Publication Date Title
JP2017501202A5 (2)
JP6475252B2 (ja) ヘテロアリール置換のニコチンアミド化合物
JP2018522859A5 (2)
JP7576552B2 (ja) イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
AU2010333804B2 (en) Fused heteroaromatic pyrrolidinones as syk inhibitors
CN111372931B (zh) 作为蛋白激酶抑制剂的杂环化合物
EP2558468B1 (en) 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
KR102319857B1 (ko) P2x7 조절제
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
JP6689871B2 (ja) Fgfr阻害剤としての二環式複素環
AU2017378943A1 (en) FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
JP2016523911A5 (2)
AU2010335556A1 (en) Imidazopyridine derivatives as JAK inhibitors
JP2018524331A5 (2)
RS54823B1 (sr) Derivati piperidin-4-il azetidina kao inhibitori jak1
AU2012323399A1 (en) 5,7-substituted-imidazo[1,2-c]pyrimidines
JP2015527399A5 (2)
TW202210466A (zh) 治療性化合物
JP2023510874A (ja) 置換ピラゾロ-ピリミジンおよびその使用
CN107108653B (zh) 吡唑并噻唑化合物及医药
JPWO2021021986A5 (2)
US9150592B2 (en) Heterocyclic nuclear hormone receptor modulators
JP2026500715A (ja) 新規ベンズイミダゾール誘導体
WO2025017078A1 (en) New pyrazolopyridine derivatives
TW202412783A (zh) 酪胺酸激酶2抑制劑及其用途